Cem GÖKÇEN, ALİ KARAYAĞMURLU, Gökay ALPAK

A Case of AripiprazoleRelated Acute Dystonia in an Adolescent Patient

Akut distonik reaksiyon (ADR) tipik antipsikotiklerle daha sık, atipik antipsikotiklerle nadir görülen ekstrapramidal bir yan etkidir. Bu reaksiyon; istemsiz, süreğen, bükücü ve döndürücü tarzda kas kasılmalarıyla karakterize, geçici anormal postürlere yol açan bir hareket bozukluğudur. Biz bu olguda 15 yaşında aripiprazol kullanımına bağlı bir ADR olgusunu paylaşacağız. Bu olgu literatürde çocuk ve ergenlerde aripiprazol kullanımına bağlı çok az ADR vakası olması nedeniyle sunulmuştur.

Ergen bir hastada aripiprazol kullanımına bağlı gelişen akut distoni olgusu

Acute dystonic reaction (ADR) is an extrapyramidal side effect, which is more commonly seen with the use of typical antipsychotics and more rarely seen with the use of atypical antipsychotics. This reaction is a movement disorder characterized by involuntary, sustained, twisting and rotating muscle contractions, which leads to temporary postural abnormalities. Here, we will present a 15-years-old subject with aripiprazol-related ADR. This case was presented since aripiprazole-related ADR in adolescents is very rare in literature.

PDF

___

Aman MG, DeSmedt G, Derivan A, Lyons B, Findling RL. Risperidone disruptive behavior study group: double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159:1337-1346.
McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 2003; 64(Suppl.4):16-25.
Stigler KA, Posey DJ, McDougle CJ. Advances in the pharmacotherapy of pervasive developmental disorder (PDD). Child Adolesc Psychopharmacol News 2003; 8:6-11.
Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second- generation antipsychotic drugs: a validity of the serotonin- dopamine hypothesis. Prog Brain Res 2008; 172:199-212.
Saha AR, Carson WH, Ali MW, Dunbar GC, Ingenito G. Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. World J Biol Psychiatry 2001; 2(Suppl.1):305.
Yeung PP, Carson WH, Saha AR, McQuade RD, Ali MW, Stringfellow JC, Ingenito G. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo-controlled trial with risperidone. Eur. Neuropsychopharmacol 2001; 11(Suppl.3):241.
Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH. A multiple- center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165:1432-1441.
Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, Aleardi M, Wozniak J. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007; 12:683-689.
Masi G, Cosenza A, Millepiedi S, Muratori F, Pari C, Salvadori F. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009; 23:511-521.
Seo WS, Sung HM, Sea HS, Bai DS. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008; 18:197-205.
Curtis AR, Richards RW. The treatment of psychogenic excoriation and obsessive compulsive disorder using aripiprazole and fluoxetine. Ann Clin Psychiatry 2007; 19:199-200.
Findling RL, Short EJ, Leskovec T, Townsend LD, Demeter CA, McNamara MK, Stansbrey RJ. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008; 18:347-354.
Ercan ES, Uysal T, Ercan E, Ardic UA. Aripiprazole in children and adolescents with conduct disorder: a single-center, open- label study. Pharmacopsychiatry 2012; 45:13-19.
Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41:1026-1036.
American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-601.
Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a bayesian meta-analysis. J Clin Psychopharmacol 2012; 32:309-316.
Imai N, Ikawa M. Efficacy of Aripiprazole in sulpiride-induced tardive oromandibular dystonia. Intern Med 2011; 50:635-637.
Saddichha S, Kumar R, Babu GN, Chandra P. Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient. J Clin Pharmacol 2012; 52:1448-1449.
Varkula M, Dale R. Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man. J Clin Psychopharmacol 2008; 28:245-247.
Sharma A, Sorrell JH. Aripiprazole-induced parkinsonism. Int Clin Psychopharmacol 2006; 21:127-129.
Singh MK, Delbello MP, Adler CM. Acute dystonia associated with aripiprazole in a child. J Am Acad Child Adolesc Psychiatry 2007; 46:306-307.
Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991; 148:85-89.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239-245.
Annagur BB, Tamam L. Bilateral Temporomandibular joint dislocation associated with use of anti-psychotic drug. Archives of Neuropsychiatry 2010; 47:351-353. (Turkish)